Heart failure continues to be a major health problem as evidenced by a rise in the number of hospitalizations for heart failure, the number of deaths attributed to heart failure, and the ever-increasing costs associated with care. Therapeutic strategies designed to coincide with the standard means of care are, therefore, needed to combat the development and progression of heart failure. Hydrogen sulfide (H 2 S) is an endogenous gaseous signaling molecule with a diverse physiological profile that has recently been shown to be cardioprotective in various models of cardiac injury. In the present study, we found that either the modulation of endogenous H 2 S production or direct pharmacologic H 2 S administration significantly reduced mortality and attenuated the severity of ischemia-induced heart failure in mice. Importantly, the present study demonstrates that although a single administration of H 2 S at the time of reperfusion is beneficial in attenuating infarct size, this alone is not sufficient to improve cardiac function significantly. On the other hand, daily H 2 S therapy for the first 7 days of reperfusion or increased endogenous H 2 S production provided significant improvements in cardiac function, suggesting that multiple therapeutic interventions are paramount for improvements in outcome. Together, these findings further support the emerging concept that H 2 S therapy may be of clinical importance in the treatment of cardiovascular disease and may have a practical clinical use after myocardial infarction to reduce the morbidity and mortality associated with ischemia-induced heart failure. See p 11.
Long-Term Localized High-Frequency Electric Stimulation Within the Myocardial Infarct: Effects on Matrix Metalloproteinases and Regional Remodeling
Adverse left ventricular remodeling after myocardial infarction (MI) remains an important cause of morbidity and mortality. Current pharmacological strategies fail to interrupt or reverse the inexorable progress of post-MI remodeling. Recent translational or early clinical research has focused on the development of new pharmacological modalities or the feasibility of delivery of exogenous cell types to prevent post-MI remodeling. However, whether endogenous cell types can be recruited and/or targeted to prevent, or even reverse, left ventricular remodeling after MI has not been explored. In the present proof-of-concept study, low-amplitude, high-frequency electric stimulation instituted within a formed MI scar arrested the progressive thinning of the MI region and attenuated left ventricular dilation. A likely mechanism for these findings was the direct effects of electric stimulation of fibroblasts/myofibroblasts resident within the MI region. These findings suggest that targeted electric stimulation of the MI region can alter the endogenous substrate for post-MI remodeling. In light of the fact that multisite myocardial pacing is a commonly used clinical tool, translational studies to extend the basic observations of the present study are warranted. See p 20.
Exercise Pulmonary Hypertension in Asymptomatic Degenerative Mitral Regurgitation
Current American College of Cardiology/American Heart Association and European Society of Cardiology guidelines recommend mitral valve surgery for asymptomatic patients with severe degenerative mitral regurgitation and preserved left ventricular systolic function when atrial fibrillation or pulmonary hypertension (PHT) is present. The American College of Cardiology/American Heart Association guidelines state that mitral valve surgery is reasonable in such patients in the presence of exercise PHT (defined as a systolic pulmonary arterial pressure Ͼ60 mm Hg, Class IIa, Level of Evidence C). In this study, 78 consecutive asymptomatic patients with preserved left ventricular systolic function and moderate or severe mitral regurgitation were submitted to resting and exercise echocardiography. The results show that exercise PHT is frequent, is related to exercise mitral regurgitation severity, and is associated with 3.4-fold increase in the risk of development of symptoms. The best cutoff value of exercise systolic pulmonary arterial pressure was 56 mm Hg, which is close to the empiric threshold of 60 mm Hg used in the American College of Cardiology/American Heart Association guidelines. We found that exercise PHT is more accurate than resting PHT for predicting symptoms. Hence, exercise echocardiography appears to be useful in patients with asymptomatic degenerative mitral regurgitation for revealing the increase in mitral regurgitation severity and the presence of PHT during exercise and thus identifying patients at risk of developing symptoms rapidly. Close follow-up (3 to 6 months) is advised in asymptomatic patients developing exercise PHT. Prompt surgery to prevent adverse left atrial remodeling, irreversible left ventricular damage, and morbid events could potentially be indicated in these patients. On the other hand, a strategy of watchful waiting seems to be more appropriate in patients without exercise PHT. See p 33.
Sirolimus-Eluting Stent Versus Balloon Angioplasty for Sirolimus-Eluting Stent Restenosis: Insights From the j-Cypher Registry
Optimal treatment strategies for restenosis of sirolimus-eluting stents (SES) have not been adequately addressed yet. A few previous small observational studies compared the use of SES for restenosis of SES with the use of balloon angioplasty (BA) in preventing recurrent target-lesion revascularization (TLR). However, there is no report from either randomized trials or large-scale observational studies investigating the efficacy of SES for restenosis associated with SES use. Our current analysis revealed that cumulative incidence of recurrent TLR in the SES-treated restenosis lesions was significantly lower than that in the BA-treated restenosis lesions (23.8% versus 37.7% at 2 years after the first TLR; PϽ0.0001). Among 33 baseline variables evaluated, only hemodialysis was identified to be the independent risk factor for recurrent TLR by a multivariable logistic regression analysis. After adjusting for confounders, repeated SES implantation was associated with a strong treatment effect in preventing recurrent TLR over BA (odds ratio, 0.44; 95% confidence interval, 0.32 to 0.61; PϽ0.0001). The 2-year mortality and stent thrombosis rates between the SES-and the BA-treated groups were 10.4% versus 10.8% (Pϭ0.4) and 0.6% versus 0.6%, respectively. Although other modalities like drug-eluting balloon catheters might be promising alternatives, our results indicate that repeated implantation of SES for SES-associated restenosis is more effective in preventing recurrent TLR than treatment with BA, without signals suggesting safety concerns. Until otherwise proven by adequately sized randomized trials, our current observation supports the choice of repeated SES implantation for SES-associated restenosis. See p 42.
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Original Research Put Into Perspective for the Practicing Clinician Baseline demographics, clinical presentation, and long-term outcome of sirolimus-eluting stent-associated ST were compared among patients with EST, LST, and VLST. Baseline demographics were significantly different according to the timing of ST. Characteristic demographic factors for LST/VLST versus EST identified by multivariable model were renal failure, absence of circumflex target, target of chronic total occlusion, prior percutaneous coronary intervention, and age Ͻ65 years. For LST versus VLST, they were hemodialysis, heart failure, insulin-dependent diabetes mellitus, and low body mass index. Patients with LST had a significantly higher rate of Thrombolysis in Myocardial Infarction grade 2/3 flow (36%) at the time of ST than those with EST (13%; PϽ0.0001) and VLST (17%; PϽ0.0001). Mortality rate at 1 year after ST was significantly lower in patients with VLST (10.5%) compared with those with EST (22.4%; Pϭ0.003) or LST (23.5%; Pϭ0.009) . From these findings, distinguishing between LST and VLST in future investigations of ST seems to be crucial. ST timing-dependent differences in baseline demographic features, Thrombolysis in Myocardial Infarction flow grade, and mortality rate suggest possible differences in the predominant pathophysiological mechanisms of ST according to timing after sirolimus-eluting stent implantation. See p 52.
Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry: A European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve
The 30-day SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry results represent the most contemporary results that can be expected with the Edwards SAPIEN valve. These data give the interventional community a benchmark from which they can assess future patient cohorts and results. In addition, they allow physicians performing this procedure to accurately refer these high-risk aortic valve patients for the transcatheter aortic valve implantation procedure. Thirty-day mortality was 8.5% overall, 6.3% for the transfemoral approach, and 10.3% for the transapical approach. The transapical patients were a higher-risk cohort; the logistic EuroSCORE was 29.1% in the transapical group and 25.7% in the transfemoral group. The stroke rate was 2.5%. The requirement for permanent pacemaker was 7%. The major vascular complication rate was 10.6% for the transfemoral approach, but unlike previous studies, this was not associated with an increased mortality. However, a major vascular complication of the transapical approach did result in increased mortality. Any future change in the technology or procedure will be able to be assessed against these results of a consecutive group of patients undergoing the procedure in centers with surgeons experienced in or new to the procedure. See p 62.
